MedTrace Logo

Control and Elimination Within Australia of Hepatitis C From People Living With HIV

NCT02102451 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 492

Last updated 2021-09-08

No results posted yet for this study

Summary

The purpose of this study is to evaluate the feasibility of rapid scale-up of new hepatitis C (HCV) treatments, known as interferon-free Direct Acting Antiviral (DAA) drugs, and impact on the proportion of people with HCV within the HIV-HCV coinfected population of Australia.

It is hypothesised that a rapid scale-up of hepatitis C treatment with interferon-free therapies in individuals with HIV-HCV coinfection will assist in controlling HCV infection in this population.

Conditions

  • Hepatitis C
  • HIV
  • HIV-HCV Coinfection

Sponsors & Collaborators

  • Kirby Institute

    lead OTHER_GOV

Principal Investigators

  • Gail Matthews, MbChB, MRCP, FRACP, PhD · Kirby Institute, University of New South Wales

  • Greg Dore, BSc, MBBS, FRACP, MPH, PhD · Kirby Institute, University of New South Wales

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-07-31
Primary Completion
2022-12-31
Completion
2022-12-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02102451 on ClinicalTrials.gov